Related Experiment Videos
Acromegalic arthropathy. Characteristics and response to therapy.
M W Layton1, E J Fudman, A Barkan
1Rackham Arthritis Research Unit, Department of Internal Medicine, University Hospital, Ann Arbor, Michigan 48109-0108.
Arthritis and Rheumatism
|August 1, 1988
Summary
Acromegaly patients often develop osteoarthritic joint pain, particularly in large joints and the spine. Growth hormone lowering therapy can improve symptoms of acromegalic arthropathy.
Area of Science:
- Endocrinology
- Rheumatology
- Orthopedics
Background:
- Acromegaly, a disorder caused by excess growth hormone, can lead to significant joint complications.
- Arthropathy is a recognized but not fully understood complication in acromegaly patients.
Observation:
- This study assessed arthropathy in 19 patients with active acromegaly.
- Arthropathy, primarily osteoarthritic, was observed in 10 patients, often affecting large joints and the lumbosacral spine.
- Patients with arthropathy had a longer mean duration of acromegaly (21.6 years) compared to those without (7.9 years).
Findings:
- Therapy aimed at lowering growth hormone production led to mild-to-moderate symptom improvement in 8 of 9 prospectively examined patients.
- Improvements were noted in symptoms, functional ability, and crepitus.
- The study suggests growth hormone lowering therapy positively impacts acromegalic arthropathy symptoms.
Implications:
- Growth hormone lowering therapy appears beneficial for managing the symptoms of acromegalic arthropathy.
- Further research is needed to determine if this therapy leads to objective structural improvements in affected joints.
- Understanding and managing arthropathy is crucial for improving the quality of life in acromegaly patients.